Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 51.39%
As of Friday, October 23, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 51.39%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Rosalio Madrigal
Michael Rose
Jenna Brashear
| Share Statistics | AARD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $20.2 | $421.5 | 12% |
|
| Shares Out (Mil) | 21.9 | 46.9 | 32% |
|
| Institutional Ownership | 62.0% | 82.0% | 39% |
|
| Float (Mil) | 12.3 | 49.2 | 22% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 392 | 347 | 54% |
|
| Price Change (52-week) |
(91.2%) | 49.3% | 5% |
|
| Growth | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | (1.3%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 6 | 9 | |
| Current EPS | ($0.801) | ($3.330) | ($2.340) | |
| Month Ago EPS | ($0.684) | ($3.029) | ($2.351) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.740) | ($3.168) | ($2.782) | |
| Year/Year Chg | (9.0%) | 13.5% | (18.8%) | |
| Financials | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($73) | ($11) | 13% |
|
| EPS (TTM) | ($3.332) | ($0.700) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($67) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $21 | $1 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | ($31) | $331 | 1% |
|
| Valuation | AARD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.35 | 2.08 | 9% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AARD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (73.5%) | (23.8%) | 7% |
|
| ROE | (80.9%) | (24.2%) | 10% |
|
| Liabilities to Assets | 11.1% | 31.6% | 7% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 11/20/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.1% |
| +/- S&P 500: | -5.3 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors